1. Home
  2. UVSP vs ABUS Comparison

UVSP vs ABUS Comparison

Compare UVSP & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Univest Financial Corporation

UVSP

Univest Financial Corporation

HOLD

Current Price

$37.58

Market Cap

983.8M

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.24

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UVSP
ABUS
Founded
1876
2005
Country
United States
United States
Employees
N/A
19
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
983.8M
848.8M
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
UVSP
ABUS
Price
$37.58
$4.24
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$36.67
$5.00
AVG Volume (30 Days)
157.8K
1.6M
Earning Date
04-22-2026
05-14-2026
Dividend Yield
2.44%
N/A
EPS Growth
21.32
55.26
EPS
0.96
0.87
Revenue
$328,056,000.00
$14,083,000.00
Revenue This Year
$11.65
N/A
Revenue Next Year
$4.77
$239.71
P/E Ratio
$39.70
$4.95
Revenue Growth
9.64
128.21
52 Week Low
$27.91
$3.04
52 Week High
$39.06
$5.10

Technical Indicators

Market Signals
Indicator
UVSP
ABUS
Relative Strength Index (RSI) 51.81 45.31
Support Level $32.00 $4.17
Resistance Level $37.72 $4.62
Average True Range (ATR) 0.68 0.16
MACD -0.19 -0.00
Stochastic Oscillator 19.66 46.23

Price Performance

Historical Comparison
UVSP
ABUS

About UVSP Univest Financial Corporation

Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: